Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lisinopril dihydrate, quantity: 21.78 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: maize starch; pregelatinised maize starch; iron oxide red; colloidal anhydrous silica; mannitol; magnesium stearate; calcium hydrogen phosphate dihydrate - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide red; colloidal anhydrous silica; mannitol; maize starch; calcium hydrogen phosphate dihydrate; pregelatinised maize starch - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lisinopril dihydrate, quantity: 5.44 mg (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: iron oxide red; calcium hydrogen phosphate dihydrate; mannitol; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; maize starch - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; iron oxide red; maleic acid; zinc stearate; iron oxide yellow; maize starch - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: hypromellose; maleic acid; iron oxide red; zinc stearate; maize starch; lactose monohydrate - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maleic acid; zinc stearate; maize starch; hypromellose; lactose monohydrate - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Malta - English - Medicines Authority

genericon pharma gesellschaft m.b.h hafnerstrasse 211, 8054 graz, austria - tadalafil - film-coated tablet - tadalafil 5 mg - urologicals

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ibuprofen, quantity: 200 mg; paracetamol, quantity: 500 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; pregelatinised maize starch; titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; purified talc; magnesium stearate; povidone; purified water; polysorbate 80; polyvinyl alcohol; macrogol 3350; mica - temporary relief of acute (short term) pain and / or inflammation associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, period pain, sore throat, tennis elbow, rheumatic pain and arthritis, and the aches and pains associated with colds and flu. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 575 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: propylene glycol; magnesium stearate; croscarmellose sodium; dichloromethane; purified talc; microcrystalline cellulose; ethylcellulose; hypromellose; isopropyl alcohol; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 1006.25 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: purified talc; propylene glycol; isopropyl alcohol; hypromellose; ethylcellulose; croscarmellose sodium; dichloromethane; microcrystalline cellulose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.